
Releases
Capricor Therapeutics Investors Face September Deadline in Securities Suit
Investors who purchased Capricor Therapeutics securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to file for lead plaintiff status. The class action, pending in the Southern District of California, follows a sharp stock decline triggered by critical FDA findings regarding the company’s lead drug candidate.


























